Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Claudia Sattlberger"'
Autor:
Georg Pfeiler, Mustafa Tukenmez, Guoping Ren, Guenther G. Steger, Alessa Heinrichs, Memduh Dursun, Qiqi Gao, Sidika Kurul, Omer Aran, Richard Greil, Anna S. Berghoff, Michael Hubalek, Hasan Karanlik, Michael Knauer, Bo Wang, Annika Waldmann, Robert M. Mader, Peyman Hadji, Telja Pursche, Jens Huober, Yulong Zheng, Florian Schuetz, Catharina De Vries, İlker Özgür, Gabriel Rinnerthaler, Cornelia Sparber, Christoph Domschke, Achim Rody, Michael Gnant, Dorothea Fischer, Simon P. Gampenrieder, Özgür Özyüncü, Elisabeth Bergen, Dilek Sahin, Matthias Kalder, Claudia Sattlberger, Zihan Wu, Beat Thürlimann, Rupert Bartsch, Margaretha Rudas, Serife Simsek, Matthias Preusser, M. Sinan Beksaç, Andrea Rottenfusser, Christian F. Singer, Christoph C. Zielinski, Flora Zagouri, Peter Dubsky, Kemal Beksac, Kristin Baumann, Florian Fitzal, Alisan Fathalizadeh, Marianne Hedderich, Derman Basaran, Constanze Banz-Jansen, Mert Turgal
Publikováno v:
Breast Care. 9:149-151
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec2619e07563a27e14d059562bf23523
https://doi.org/10.1159/000365856
https://doi.org/10.1159/000365856
Autor:
Claudia Sattlberger, Michael Gnant, Rupert Bartsch, Margaretha Rudas, Elisabeth Bergen, Peter Dubsky, Catharina De Vries, Cornelia Sparber, Anna S. Berghoff, Matthias Preusser, Christoph C. Zielinski, Guenther G. Steger, Robert M. Mader, Florian Fitzal, Andrea Rottenfusser, Flora Zagouri
Background: This retrospective analysis was planned as a direct comparison of taxanes plus trastuzumab to the less toxic combination of oral vinorelbine (OV) plus trastuzumab as a first-line therapy for metastatic HER2-positive breast cancer. Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a67fb3f3a07def6412ac548450d8b56
https://europepmc.org/articles/PMC4322687/
https://europepmc.org/articles/PMC4322687/
Autor:
Simon Peter, Gampenrieder, Franz, Romeder, Claudia, Muß, Magdalena, Pircher, Sigrun, Ressler, Gabriel, Rinnerthaler, Rupert, Bartsch, Claudia, Sattlberger, Brigitte, Mlineritsch, Richard, Greil
Publikováno v:
Anticancer research. 34(1)
Several phase-III studies have shown improvements in terms of progression-free survival (PFS) with bevacizumab when added to chemotherapy in advanced breast cancer. However, the extent of improvement varied and none of the trials showed benefit in te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::63fa6de376bf13005c6d671f60bbe701
https://pubmed.ncbi.nlm.nih.gov/24403467
https://pubmed.ncbi.nlm.nih.gov/24403467
Autor:
Robert M. Mader, C. DeVries, Guenther G. Steger, Michael Gnant, Andrea Rottenfusser, Christoph Minichsdorfer, Matthias Preusser, Christoph C. Zielinski, Claudia Sattlberger, Zsuzsanna Bago-Horvath, Anna S. Berghoff, Peter Dubsky, Cornelia Sparber, Florian Fitzal, Rupert Bartsch, Margaretha Rudas
Publikováno v:
Web of Science
573 Background: ER cross-activation by growth-factor signalling causes resistance to endocrine therapy (ET) in patients (pts) with Her2-positive MBC. Moreover, low levels of Her2-expression (Her2 1+; Her2 2+ without gene amplification), may result in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a33762a4af690b7f9ddcee1678e12d4
https://doi.org/10.1200/jco.2013.31.15_suppl.573
https://doi.org/10.1200/jco.2013.31.15_suppl.573